Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Models, Models, Everywhere: But Which One Should Guide Care?

Blood cancer discovery - 5 May 2026

Lachowiez Curtis A, Loghavi Sanam

Abstract excerpt

Drekolias and colleagues report a therapy-specific prognostic model integrating mutational and cytogenetic features to risk-stratify survival in patients with acute myeloid leukemia treated with venetoclax-based regimens, providing a clinically relevant framework amid a rapidly expanding landscape of competing models. See related article by Drekolias et al., p. 403.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Sulfonamides

Source

Identifiers

PMID: 41914836
DOI: 10.1158/2643-3230.BCD-26-0055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Models, Models, Everywhere: But Which One Should Guide Care?PMID 41914836Read ↗

Development of a dynamic counterfactual risk stratification strategy for newly diagnosed acute myeloid leukemia patients treated with venetoclax and azacitidineSemantic proximity Read ↗

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG ReportSemantic proximity Read ↗

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read ↗

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Semantic proximity Read ↗

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity Read ↗

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.Semantic proximity Read ↗

Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort StudySemantic proximity Read ↗

Prognostic models in the myeloproliferative neoplasms.Semantic proximity Read ↗

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemiaSemantic proximity Read ↗

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite modelSemantic proximity Read ↗

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemiaSemantic proximity Read ↗

A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.